A novel use of combined tyrosine hydroxylase and silver nucleolar staining to determine the effects of a unilateral intrastriatal 6-hydroxydopamine lesion in the substantia nigra: A stereological study

Journal of Neuroscience Methods

Volumn 210, Issue 2, 2012, Pages 187-194

  Healy Stoffel, Michelle ^a   Ahmad, S Omar ^b   Stanford, John A ^a   Levant, Beth ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

Author keywords

6 Hydroxydopamine; 6 OHDA; AgNOR; HPLC EC; Neuronal number; Neuronal volume; NOR; Silver nucleolar stain; SNpc; Stereology; Substantia nigra pars compacta; TH; TH AgNOR

Indexed keywords

DEXAMPHETAMINE; DOPAMINE; OXIDOPAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; CELL COUNT; CELL STRUCTURE; DOPAMINERGIC NERVE CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SILVER NUCLEOLAR STAINING; STAINING; STEREOLOGY; SUBSTANTIA NIGRA PARS COMPACTA; TYROSINE 3 MONOOXYGENASE STAINING;

EID: 84865438509     PISSN: 01650270     EISSN: 1872678X     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2012.07.013     Document Type: Article

References (37)

1. Ahmad S., Park J., Radel J., Levant B. Reduced numbers of dopamine neurons in the substantia nigra pars compacta and ventral tegmental area of rats fed an n-3 polyunsaturated fatty acid-deficient diet: a stereological study. Neurosci Lett 2008, 438:303-307.
2. Bethel-Brown C.S., Morris J.K., Stanford J.A. Young and middle-aged rats exhibit isometric forelimb force control deficits in a model of early-stage Parkinson's disease. Behav Brain Res 2011, 225:97-103.
3. Bethel-Brown C.S., Zhang H., Fowler S.C., Chertoff M.E., Watson G.S., Stanford J.A. Within-session analysis of amphetamine-elicited rotation behavior reveals differences between young adult and middle-aged F344/BN rats with partial unilateral striatal dopamine depletion. Pharmacol Biochem Behav 2010, 96:423-428.
4. Calne D., Langston J. Aetiology of Parkinson's disease. Lancet 1983, 2:1457-1459.
5. Carvalho G.A., Nikkhah G. Subthalamic nucleus lesions are neuroprotective against terminal 6-OHDA-induced striatal lesions and restore postural balancing reactions. Exp Neurol 2001, 171:405-417.
6. Davis P.F., Ozias M.K., Carlson S.E., Reed G.A., Winter M.K., McCarson K.E., et al. Dopamine receptor alterations in female rats with diet-induced decreased brain docosahexaenoic acid (DHA): interactions with reproductive status. Nutr Neurosci 2010, 13:161-169.
7. Debeir T., Ginestet L., François C., Laurens S., Martel J.C., Chopin P., et al. Effect of intrastriatal 6-OHDA lesion on dopaminergic innervation of the rat cortex and globus pallidus. Exp Neurol 2005, 193:444-454.
8. Derenzini M., Ceccarelli C., Santini D., Taffurelli M., Treré D. The prognostic value of the AgNOR parameter in human breast cancer depends on the pRb and p53 status. J Clin Pathol 2004, 57:755-761.
9. Derenzini M., Trerè D., Pession A., Govoni M., Sirri V., Chieco P. Nucleolar size indicates the rapidity of cell proliferation in cancer tissues. J Pathol 2000, 191:181-186.
10. Deumens R., Blokland A., Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 2002, 175:303-317.
11. Eriksen N., Stark A.K., Pakkenberg B. Age and Parkinson's disease-related neuronal death in the substantia nigra pars compacta. J Neural Transm Suppl 2009, 203-213.
12. Glinka Y., Gassen M., Youdim M.B. Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm Suppl 1997, 50:55-66.
13. Gomide V., Bibancos T., Chadi G. Dopamine cell morphology and glial cell hypertrophy and process branching in the nigrostriatal system after striatal 6-OHDA analyzed by specific sterological tools. Int J Neurosci 2005, 115:557-582.
14. Gundersen H.J., Bagger P., Bendtsen T.F., Evans S.M., Korbo L., Marcussen N., et al. The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 1988, 96:857-881.
15. Kilts C.D., Breese G.R., Mailman R.B. Simultaneous quantification of dopamine, 5-hydroxytryptamine and four metabolically related compounds by means of reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr 1981, 225:347-357.
16. Kirik D., Rosenblad C., Björklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 1998, 152:259-277.
17. Kostrzewa R.M., Jacobowitz D.M. Pharmacological actions of 6-hydroxydopamine. Pharmacol Rev 1974, 26:199-288.
18. Kuhn C.M., Schanberg S.M. Metabolism of amphetamine after acute and chronic administration to the rat. J Pharmacol Exp Ther 1978, 207:544-554.
19. Lee C.S., Sauer H., Bjorklund A. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by instrastriatal 6-hydroxydopamine in the rat. Neuroscience 1996, 72:641-653.
20. Levant B., Ozias M.K., Davis P.F., Winter M., Russell K.L., Carlson S.E., et al. Decreased brain docosahexaenoic acid content produces neurobiological effects associated with depression: interactions with reproductive status in female rats. Psychoneuroendocrinology 2008, 33:1279-1292.
21. Levant B., Zarcone T.J., Davis P.F., Ozias M.K., Fowler S.C. Differences in methylphenidate dose response between periadolescent and adult rats in the familiar arena-novel alcove task. J Pharmacol Exp Ther 2011, 337:83-91.
22. Lindner M.D., Cain C.K., Plone M.A., Frydel B.R., Blaney T.J., Emerich D.F., et al. Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats. Behav Brain Res 1999, 102:1-16.
23. Marsden C.D. Parkinson's disease. Lancet 1990, 335:948-952.
24. Paxinos G. The rat nervous system 1995, Academic Press, San Diego. 2nd ed.
25. Przedborski S., Vila M., Jackson-Lewis V. Neurodegeneration: what is it and where are we. J Clin Invest 2003, 111:3-10.
26. Rodríguez M., Barroso-Chinea P., Abdala P., Obeso J., González-Hernández T. Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in parkinson's disease. Exp Neurol 2001, 169:163-181.
27. Rudow G., O'Brien R., Savonenko A.V., Resnick S.M., Zonderman A.B., Pletnikova O., et al. Morphometry of the human substantia nigra in ageing and Parkinson's disease. Acta Neuropathol 2008, 115:461-470.
28. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994, 59:401-415.
29. Schmitz C., Hof P.R. Design-based stereology in neuroscience. Neuroscience 2005, 130:813-831.
30. Stark A.K., Pakkenberg B. Histological changes of the dopaminergic nigrostriatal system in aging. Cell Tissue Res 2004, 318:81-92.
31. Sterio D.C. The unbiased estimation of number and sizes of arbitrary particles using the disector. J Microsc 1984, 134:127-136.
32. Switzer R.C., Baun J., Tipton B., Segovia C., Ahmad S.O., Benkovic S.A. Modification of AgNOR staining to reveal the nucleolus in thick sections specified for stereological assessment of dopaminergic neurotoxicity in substantia nigra, pars compacta. Soc Neurosci Abst 2011, 304-305. 2011 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience. Online.
33. Trerè D. AgNOR staining and quantification. Micron 2000, 31:127-131.
34. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 1970, 24:485-493.
35. West M.J. New stereological methods for counting neurons. Neurobiol Aging 1993, 14:275-285.
36. Widerlöv E., Kilts C.D., Mailman R.B., Nemeroff C.B., Mc Cown T.J., Prange A.J., et al. Increase in dopamine metabolites in rat brain by neurotensin. J Pharmacol Exp Ther 1982, 223:1-6.
37. Ybot-Gorrin I., Vivancos-Matellano F., Chacón-Peña J.R., Alonso-Navarro H., Jiménez-Jiménez F.J. Assessment of Parkinson disease: what do we need to show neuroprotection. Neurologist 2011, 17:S21-S29.